Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

Johann S. de Bono; Shahneen Sandhu; Gerhardt Attard

doi:10.1016/j.ccr.2011.05.003

Related publications

Article2013

Predictive biomarkers for cancer therapy with PARP inhibitors

Judith Michels, Ilio Vitale, Murat Saparbaev, Maria Castedo, Guido Guido Kroemer

Article2022

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

Andrisha–Jade Inderjeeth, Monique Topp, Elaine Sanij, Elena Castro, Shahneen Sandhu

Letter2013

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Shahneen Sandhu, Aurelius Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa, Heidi Gevensleben, James Campbell, Kerry Fenwick, Ioannis Assiotis, David Olmos, Timothy A. Yap, Peter C.C. Fong, Nina Tunariu, Dow‐Mu Koh, L. Rhoda Molife, S.B. Kaye, Christopher J. Lord, Alan Ashworth,

Article2004

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

Raymond P. Abratt, D. Brune, Meletios A Dimopoulos, J. Kliment, J. Breza, Fp Selvaggi, Philippe Beuzeboc, Tomasz Demkow, Stéphane Oudard

Article2019

PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer

Laura H. Porter, Mitchell G. Lawrence, Nicholas Choo, Shahneen Sandhu, Hong Wang, David Pook, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Luc Furic, Renea A. Taylor, Gail P. Risbridger